Feasibility of Use of Vibrators With Vaginal Dilators for Vaginismus. (Vibrator Therapy and Dilators in Vaginismus)

A Pilot Study Assessing the Feasibility of Using Clitoral Vibrators to Aid Vaginal Dilator Therapy in Women Presenting to Psychosexual Services With Vaginismus.

Sponsors

Lead Sponsor: Barts & The London NHS Trust

Source Barts & The London NHS Trust
Brief Summary

The acceptability of vulvar vibration therapy has been evaluated in women with vulvodynia, and found to be acceptable, however has not been assessed in women with a primary complaint of vaginismus. This proposed study looks at the feasibility and acceptability of using clitoral vibration therapy, alongside current therapy, for women with vaginismus. It is likely that many, if not most, of these women will also have an element of vulvodynia. The investigators propose that the use of external clitoral or vulval vibration therapy is likely to be acceptable in most women with vaginismus, based on acceptability of vulvar vibration therapy in women with vulvodynia. It is proposed that vibrator therapy may help women with female sexual dysfunction to use vaginal dilators.

Detailed Description

This is a nonrandomized controlled trial, with the initial cluster of patients receiving standard therapy, and the second cluster receiving standard therapy plus vibrator. Recruitment will be an initial 15 participants who will receive standard therapy, and then another 15 who will receive an external vibrator. This study will take place over approximately 12 months. Enrollment of patients will be from a joint psychosexual clinic led by a medical doctor and a clinical psychologist. Female patients are referred to this clinic by General Practitioners, from within the Sexual Health service, or via Gynaecologists, frequently with complaint of difficulty or pain with penetrative sex. Exclusion criteria will be: patients unable/ unwilling to consent, transgender male or on testosterone therapy, unable to understand written and/or verbal English, current dermtatological skin conditions requiring active treatment, genital herpes simplex virus within 3 months, or not reporting symptoms of vaginismus with no evidence of vaginismus on clinical examination. Trial information will be given at the initial appointment. If the patient wishes to enrol, than an initial baseline questionnaire will be given, and a follow up questionnaire will be filled out by phone contact at 3-4 months afterward the initial consultation at the patients consent.

Overall Status Not yet recruiting
Start Date 2021-04-01
Completion Date 2022-04-01
Primary Completion Date 2022-04-01
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Is vibration therapy (through the use of handheld external vibrators on clitoral and vulval area) acceptable to women as part of medical management of vaginismus and vaginismus/vulvodynia, alongside current medical management? 12-18 months
Secondary Outcome
Measure Time Frame
Does the use of clitoral/ vulval vibrators help women to progress more easily with the use of vaginal dilators compared to women not using these? 12-18 months
Is there any self-reported difference in experiences of pleasure or enjoyment around sexual experiences in the two groups of women as reported by FSDS (Female Sexual Distress Scale) Scores? 12-18 months
Is there any self-reported difference in experiences of pleasure or enjoyment around sexual experiences in the two groups of women as reported by FSFI (Female Sexual Function Index) Scores? 12-18 months
Enrollment 30
Condition
Intervention

Intervention Type: Other

Intervention Name: External Vibrator - patient-administered.

Description: Patient provided with external vibrator for self-use, as well as vaginal dilators.

Arm Group Label: Vibrator Therapy + dilator/standard therapy

Intervention Type: Other

Intervention Name: Standard care

Description: Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.

Eligibility

Criteria:

Inclusion Criteria: - Able and willing to give informed consent (additional measures have to be in place if children, vulnerable adults or adults unable to give consent are included) - Female - Over the age of 18 - With symptoms and clinical signs consistent with vaginismus/ vaginismus and vulvodynia. Exclusion Criteria: - Unwilling or unable to give consent - Transgender male / on testosterone therapy - Inability to understand written and / or verbal English - Current dermatological skin conditions requiring active treatment - Genital herpes simplex virus symptoms within preceding 3 months - Not reporting symptoms of vaginismus, and no evidence of vaginismus on clinical examination.

Gender:

Female

Minimum Age:

18 Years

Maximum Age:

90 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Jess Gaddie Principal Investigator Barts & The London NHS Trust
Overall Contact

Last Name: Jessica Gaddie, MbCHb, BSc

Phone: 0207 377 7315

Email: [email protected]

Verification Date

2020-08-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Vibrator Therapy + dilator/standard therapy

Type: Experimental

Description: Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel) plus an external vibrator.

Label: Dilator/standard therapy

Type: Active Comparator

Description: Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel).

Acronym ViTaDiVa
Patient Data No
Study Design Info

Allocation: Non-Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Other

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News